Recent work has proposed VIP, one of the major peptide transmitters in the central and peripheral nervous system, as a promising agent for the treatment of chronic airway disease including asthma [35] and COPD [36], [37] based on its combined bronchodilatory and immunomodulatory properties. The gene discussed is VIP; the disease is chronic obstructive pulmonary disease.